Clinical Trial

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-17; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT06891885
Lead Sponsor Sumitomo Pharma America, Inc.
Conditions Retinitis Pigmentosa
Enrollment 12 participants
Start Date 2026-04-16
Primary Completion 2028-10-31 (estimated)
Study Completion 2032-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-17